Teva Pharmaceutical Industries Balance Sheet Health
Financial Health criteria checks 3/6
Teva Pharmaceutical Industries has a total shareholder equity of $7.5B and total debt of $20.0B, which brings its debt-to-equity ratio to 265.9%. Its total assets and total liabilities are $42.1B and $34.6B respectively. Teva Pharmaceutical Industries's EBIT is $2.6B making its interest coverage ratio 2.8. It has cash and short-term investments of $2.2B.
Key information
265.9%
Debt to equity ratio
US$19.97b
Debt
Interest coverage ratio | 2.8x |
Cash | US$2.25b |
Equity | US$7.51b |
Total liabilities | US$34.58b |
Total assets | US$42.09b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: TEV's short term assets ($11.4B) exceed its short term liabilities ($11.4B).
Long Term Liabilities: TEV's short term assets ($11.4B) do not cover its long term liabilities ($23.2B).
Debt to Equity History and Analysis
Debt Level: TEV's net debt to equity ratio (236%) is considered high.
Reducing Debt: TEV's debt to equity ratio has increased from 154.1% to 265.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable TEV has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: TEV is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 24.9% per year.